A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

Explore causes, symptoms and diagnosis of Giant Cell Arteritis and Temporal Arteritis including headache, vision loss and jaw pain linked to artery inflammation ...

Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of ...

In giant cell arteritis, immune cells react against blood vessels and make them inflamed. Doctors don't know what triggers this, but you're more likely to get it if you're: Over 50; ...

The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK ...

Giant cell arteritis (GCA) is the most common form of vasculitis in the older adult population. There are variable clinical presentations of this entity and no perfect diagnostic test, often ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck.

Temporal arteritis, or giant cell arteritis, is a vascular condition that causes headaches and pain when the arteries in the head become inflamed. What causes it is unclear, but medical care is ...

Find the latest Vasculitis and Giant Cell Arteritis news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

Frailty is common in rheumatic diseases and linked to worse outcomes. Early screening and targeted prevention can improve ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA ...